We introduce an engineered nanobody whose affinity to green fluorescent protein 24 (GFP) can be switched on and off with small molecules. By controlling the cellular 25 localization of GFP fusion proteins, the engineered nanobody allows to study their role 26 in basic biological processes, an approach that should be applicable to numerous 27 previously described GFP fusions. We also outline how the binding affinities of other 28 nanobodies can be controlled by small molecules. 29 30 Supplementary Fig. 1) . The most promising insertion hits were in the 55 complementary-determining region 3 (CDR3), which is often essential for making 56 high affinity contacts between nanobodies and their targets 11 . Of these hits, we 57 analyzed GFP LAMAF98, GFP LAMAG97, and GFP LAMAN95 in greater detail (Fig. 1c-e and  58   Supplementary Fig. 2) . All three GFP LAMAs retained a single-digit nanomolar affinity 59 to GFP in the absence of ligands. For all three nanobodies, the affinity towards GFP 60 was dramatically decreased in the presence of NADPH and TMP such that no 61 binding to GFP could be detected for GFP LAMAF98 and GFP LAMAG97 (Fig. 1c-e and 62 Supplementary Fig. 3) . For GFP LAMAF98 the presence of NADPH alone also 63 affected the binding affinity to GFP, whereas the affinity of GFP LAMAG97 and 64 GFP LAMAN95 was not affected by NADPH. 65
MAIN TEXT 31
The variable domains of heavy chain-only antibodies 1 , commonly abbreviated as 32 nanobodies, are powerful tools to interrogate processes in living systems. 33
Nanobodies can be selected to bind to a variety of targets with high affinity and 34 selectivity, and can be functionally expressed inside cells 2,3 . The range of 35 applications of nanobodies would be greatly expanded if their binding affinity towards 36 their target could be rapidly switched on and off with a cell-permeable and non-toxic 37 molecule. Proteins such as kinases and Cas9 have been engineered to control their 38 activity with small molecules 4-6 , but these approaches have not been applied to 39 nanobodies. Here, we introduce "ligand-modulated antibody fragments" (LAMAs), 40 which combine the high selectivity and specificity of nanobodies with the fast 41 temporal control offered through the use of small molecules. LAMAs are generated 42 by inserting a circularly permutated bacterial dihydrofolate reductase (cpDHFR) 7 into 43 nanobodies. The new termini of this cpDHFR are located in an active site loop of 44 wild-type DHFR. Furthermore, cpDHFR is partially unfolded in the absence of its 45 cofactor nicotinamide adenine dinucleotide phosphate (NADPH) and DHFR inhibitors 46 such as trimethoprim (TMP) 8, 9 . TMP is a clinically approved anti-bacterial drug that 47 has excellent cell and tissue permeability and is not toxic for mammalian cells. 48
LAMAs disrupt the binding of the nanobody to its target by exploiting the change in 49 conformation of cpDHFR upon binding of NADPH and DHFR inhibitors (Fig. 1a) . The 50 first nanobody we subjected to this approach was the enhancer nanobody for GFP 10 . 51
Specifically, we inserted cpDHFR into various sites of the enhancer nanobody and 52 measured the binding affinities of the protein chimeras to wild-type GFP (wtGFP) in 53 the presence and absence of the ligands NADPH and TMP ( Fig. 1b and  54 66
The kinetics of dissociation of the complexes between GFP and GFP LAMAF98 or 67 GFP LAMAG97 upon addition of TMP were on the timescale of minutes: t1/2 = 34 ± 1 sec 68 and t1/2 = 5.6 ± 0.5 min for GFP LAMAF98 and GFP LAMAG97, respectively ( Fig. 1f,g) . 69
Subsequent removal of TMP by addition of wild-type DHFR resulted in reformation of 70 the complexes within minutes ( Fig. 1f,g) . The complex could then be dissociated 71 again by addition of an excess amount of TMP ( Fig. 1f,g) . The dissociation kinetics 72 of the complexes could also be tuned using DHFR inhibitors with different affinities to 73 DHFR (Supplementary Fig. 4) . These experiments underline that GFP LAMAF98 and 74 GFP LAMAG97 can be repeatedly switched on and off through the addition of DHFR 75 inhibitors. 76
77
To understand how the cpDHFR insertion into nanobodies allowed control of binding 78 affinities, we solved the crystal structures of GFP LAMAF98 and GFP LAMAG97 in complex 79 with NADPH and TMP. No major structural changes were seen in the nanobody 80 domain of the two LAMAs relative to enhancer nanobody. Comparing these 81 structures with the structure of enhancer nanobody bound to GFP suggests that 82 folded cpDHFR sterically hampers binding to GFP ( Fig. 1h and Supplementary Fig.  83   5) . The TMP-dependent control of the GFP LAMAs was abolished when GGS-linkers 84 were inserted between cpDHFR and the nanobody (Supplementary Fig. 6) , 85
indicating that the switching of nanobody affinity did not solely arise from insertion of 86 the protein domain. 87
88
Given the large number of nanobodies that have been selected and characterised 12 , 89 we attempted to expand the LAMA concept to other targets. Nanobodies for G-90 associated kinase 13 , and for lamina-associated polypeptide 1 14 , did not allow for 91 cpDHFR insertion into the tried positions ( Supplementary Fig. 7a,b) . The minimizer 92 nanobody for GFP 10 greatly decreased its affinity to GFP on cpDHFR insertion, but 93
responded to the addition of ligands ( Supplementary Fig. 7c ). A nanobody for the 94 C-terminal region of the p24 HIV capsid protein (manuscript in preparation) could be 95 readily converted into a LAMA on insertion of cpDHFR into the CDR3 loop ( Fig. 1i  96 and Supplementary Fig. 8 ). The p24 LAMAS98 showed low nanomolar affinity for p24 97 HIV capsid protein when no ligands were present. Neither TMP nor NADPH alone 98 could decrease the affinity of p24 LAMAS98 for its target, but addition of both ligands 99 reduced the affinity 70-fold ( Fig. 1j) . These experiments highlight the transferability 100 for the LAMA approach to other nanobodies. 101
102
The binding of both the p24 LAMA and GFP LAMAs to their targets could be switched on 103 and off through the addition of TMP in live cells (Fig 2) . Intracellular NADPH 104 concentration in live cells is estimated to be 3.1 ± 0.3 µM 15 , thus providing a basal 105 level of NADPH. The expression of the cytosolic p24 precursor polyprotein Gag in 106 HIV transfected cells stably expressing an EGFP-p24 LAMAS98 fusion resulted in 107 sequestering of the LAMA in the cytosol ( Fig. 2a) . However, the LAMA was released 108 from the p24 domain of Gag by the addition of TMP within minutes, as demonstrated 109 by diffusion of EGFP-p24 LAMAS98 into the nucleus ( Fig. 2a and Supplementary Fig.  110 9). Targeting GFP LAMAs to the inner leaflet of the plasma membrane by a Lyn kinase 111 derived sequence 16 (Lyn-GFP LAMA) resulted in localization of EGFP to the plasma 112 membrane, which could be released into the cytosol through addition of TMP ( Fig.  113 2b and Supplementary Fig. 10a ). Similarly, targeting GFP LAMAs to the outer 114 membrane of mitochondria 17 (mito-GFP LAMAs) resulted in reversible sequestering of 115 EGFP to the outer membrane of mitochondria ( Fig. 2c and Supplementary Fig. 10b  116 ). The kinetics of the TMP-dependent release and sequestering of EGFP from the 117 outer mitochondrial membrane was evaluated by following the appearance and 118 disappearance of the fluorescence of nuclear EGFP (Fig. 2d,e and Supplementary 119 Fig. 11) . The release and sequestering of EGFP upon addition and wash-out of TMP 120 occurred on a timescale of minutes, and could be repeated over several cycles ( Fig.  121 2e). Furthermore, TMP-dependent release of EGFP from mito-GFP LAMAF98 was 122 dose-dependent up to 5 µM TMP ( Supplementary Fig. 11b ). 123 124 GFP LAMAs can be used to control the localization of other family members of GFP-125 based proteins to which the enhancer nanobody binds, for example YFP and 126 Shadow G 18 , a non-fluorescent version of GFP ( Fig. 2f and Supplementary Fig.  127 12). The high affinity of GFP LAMAs for GFP also allows to mislocalize GFP fusion 128 proteins that are part of larger protein complexes. For example, transient transfection 129 of mito-GFP LAMAF98 into a genome-edited cell line expressing NUP62-mEGFP 130 ( Supplementary Fig. 13a ), a component of the nuclear pore complex, resulted in 131 sequestering of NUP62-mEGFP from the nuclear envelope to the mitochondria in the 132 absence of TMP (Fig 2g and Supplementary Fig. 13b ). Upon addition of TMP, 133 NUP62-mEGFP localized to the nuclear membrane. (Fig 2h and Supplementary Fig. 14) . Knock-down of Mad2L1 reduces 140 mitotic duration and increases the percentage of polylobed nuclei 19 . A HeLa Kyoto 141 cell line in which endogenous Mad2L1 has been tagged with EGFP has been 142 previously described and used to map the localizations of Mad2L1 during mitosis 20 . 143
We stably expressed mito-GFP LAMAF98 in the Mad2L1-EGFP cell line, and observed 144 how sequestering Mad2L1-EGFP to the mitochondria affected the outcome of cell 145 division ( Supplementary Fig. 15 and Supplementary Video 1-4). In the absence of 146 TMP, we observed an increase in the percentage of polylobed nuclei following 147 mitotic events relative to cells not expressing mito-GFP LAMAF98 (85 ± 13 % vs. 10 ± 6 148 %; Fig. 2i and Supplementary Fig. 16 ). Addition of TMP to cells expressing mito-149 GFP LAMAF98 reduced the levels to those not expressing mito-GFP LAMAF98 (10 ± 11 150 %). Next, nocodazole, a small molecule which prevents attachment of microtubules 151 to kinetochores, was added to activate the mitotic checkpoint complex. After 152 treatment with nocodazole, cells in which Mad2L1-EGFP had been sequestered at 153 the mitochondria were able to override mitotic arrest whereas treatment with 154 nocodazole and TMP lead to mitotic arrest, as expected ( Fig. 2j and 155 Supplementary Fig 17) . These data show that the function of Mad2L1-EGFP in the 156 mitotic checkpoint complex can be controlled through its TMP-dependent interaction 157 with mito-GFP LAMAF98. 
DNA plasmids and molecular cloning 294
Plasmids were generated using standard molecular biology techniques. All subcloned 295 sequences were verified using Sanger sequencing, assisted by Geneious software 296 (Biomatters). pCHIV is a non-infectious HIV-1 viral construct lacking LTRs and the nef 297 were made fresh before use. Fluorescent dyes for live-cell imaging were purchased 311 from available suppliers, or were synthesized as previously described 25, 26 . 312 313
Protein purification 314
Proteins were expressed using a pET51b(+) (Novagen) in Escherichia coli BL21 (DE3) 315 pLysS, in the presence of 100 µg mL -1 ampicillin in Luria-Bertani, shaking at 220 rpm. 316
Cultures were grown at 37 °C until an OD600 of 0.8 was reached, and then induced 317 with 1 mM isopropyl β-thiogalacopyranoside (ITPG). After overnight expression at 25 318 °C, cells were harvested and lysed by sonication. The lysates were cleared by 319 centrifugation and purified by IMAC using Ni-NTA Resin (Thermo Fisher Scientific). 320
For proteins used in TR-FRET assays, His-tag purification was followed by Strep-321
Tactin purifications (IBA Lifesciences), according to the manufacturer's protocol. 470 nm (5 nm bandwidth). Emission wavelength was 535 nm (5 nm bandwidth). For 364 reversible association eDHFR was diluted in 50 mM HEPES, 50 mM NaCl, 0.5 mg mL -365 1 BSA, 0.05% Triton-X 100 and 1 µL added to the reaction mix in the 96-well plate. 366
The curves where fit with one-phase dissociation models to estimate the half time at 367 these concentrations. 368 369
Protein crystallization 370
For X-ray crystallography, the LAMAs were sub-cloned into a vector carrying an N-371
terminal Hisx10-tag, followed by a tobacco etch virus (TEV) protease cleavage tag 372 sequence. The production and IMAC purification of the TEV protease was performed 373
as previously described 28 . The His-Tag was removed from the LAMAs by TEV 374 protease cleavage at 30 °C overnight, at a ratio of 1:20 (TEV protease: LAMA). The 375 digested protein was purified using a reverse IMAC purification method by NTA resin, 376 collecting the flow-through. The protein was passed over a size-exclusion column and 377 concentrated using centrifugal filter units (Amicon). The protein was flash-frozen and 378 stored at -70 °C. Purified protein in 25 mM HEPES, 25 mM NaCl, pH 7.3 was premixed 379 with NADPH (10 eq) and TMP (10 eq) as solid powders in 300 µL volume. The solution 380 was left on ice for 10 minutes before centrifugation (20 000g, 10 min, 4 °C) to remove 381 any precipitation. 
X-ray diffraction data collection and structure determination 399
Single crystal X-ray diffraction data were collected at 100 K on the X10SA beamline 400 at the SLS (PSI, Villigen, Switzerland). All data were processed with XDS 29 . The medium supplemented with 10% FBS, and penicillin and streptomycin as indicated, at 419 37 °C in a humidified incubator with 5% CO2. All cells were mycoplasma-free. 420 421
Generation of p24 LAMAs98 cell lines 422
Lentiviral particles were generated by co-transfection of transfer plasmid pWPI EGFP-423 p24 LAMAS98 IRES puro, packaging construct psPAX2, fusion protein expression 424 plasmid pCMV-VSVG and pAdvantage (Promega) in a ratio of 1.5 : 1 : 0.5 : 0.2, into 425 HEK293T (ATCC) cells using PEI (1:3 ratio of µg DNA : µl 1 mg/ml PEI). The medium 426 was changed after 6 hours and production of lentiviral particles was allowed to proceed 427 for 48 h. The supernatant was filtered through 0.45 µm MCE filters and was directly 428 added to HeLa TZM-bl cells (NIH AIDS Repository). After 2 days the cells were 429 expanded and 1 µg/ml puromycin was added to select for stably transduced cells. 430 431
Genome editing 432
Nup62 in HeLa Kyoto cells was endogenously tagged with mEGFP at the C-terminus 433 by CRISPR-Cas9 nickases and its homozygous integration was validated as 434 described previously 36, 37 . The gRNA sequences for the genome editing are as follows: 435 5'TCGCTCAGTCAAAGGTGATC3' and 5'CTGGGGCCCGCAGGTCCCTA3'. 436
Previously described genome edited HeLa Kyoto Mad2L1-EGFP 20 were used in the 438 generation of stable cell lines expressing LAMAs. HeLa Kyoto Mad2L1-EGFP cells 439 were seeded one day before transfection with Lipofectamin3000 (Thermo Fisher 440 Scientific), in the presence of TMP (10-50 µM), following the manufacturer's 441 instructions. Cells were seeded monoclonal densities and selected using 500-800 µg 442 mL -1 geneticin (Thermo Fisher Scientific), and TMP (10-50 µM) for 2 weeks. Cells were 443 then labeled with BG-SiR (500 nM) overnight, before sorting on a FACSMelody (BD 444 biosciences) for LAMA expressing cells. 445 446 447
Live cell imaging of p24 LAMAS98 in HIV expressing cells 448
HeLa TZM-bl cells were seeded the day before transfection in complete medium with 449 100 U/ml penicillin 100 µg/ml streptomycin and incubated at 37 °C and 5 % CO2. 450 pCHIV env(stop) was transfected in a 1:1 ratio with pCHIV env(stop) gag-mCherry 451 using Turbofect (1:2 ratio). The cells were incubated for 24 hours, the medium was 452 changed to imaging medium (FluoroBrite DMEM (Thermo Fisher Scientific), 10 % 453 FBS, 4 mM GlutaMAX (Gibco Life Technologies), 2 mM sodium pyruvate (Gibco Life 454 Technologies), 20 mM HEPES pH 7.4, 100 U/ml Penicillin 100 µg/ml Streptomycin 455 (PAN-Biotech, Germany)) and transferred to a Nikon Eclipse Ti2 (Nikon, Japan) 456 inverted microscope equipped with an Andor confocal spinning disc unit (Yokogawa 457 CSU-W1 Spinning Disk Unit, Andor, Oxford Instruments, United Kingdom). Cells were 458 imaged at 37 °C and 5 % CO2 using a 100 × oil-immersion objective (Nikon CFI 459
Apochromat TIRF 100X Oil NA 1.49) and a dual EMCCD camera setup (ANDOR iXon 460
Live-cell imaging of Nup62-mEGFP 509
Live-cell imaging of HeLa Nup62-mEGFP cells was performed at 37 °C in CO2-510 independent medium without phenol red (Invitrogen, Carlsbad, CA) containing 20% 511 FBS, 2 mM l-glutamine, and 100 µg/ml penicillin and streptomycin, with either 10 µM 512 of TMP or DMSO. Cells were incubated with 10 µM BG-TMR for 30 min and the BG-513 TMR was washed away before imaging. Cells were then observed by confocal 514 microscopy (LSM780; Carl Zeiss, Oberkochen, Germany) using a 63 × 1.4 NA Plan-515
Apochromat objective (Carl Zeiss), recording the mEGFP (488/491-552 nm) and TMR 516 (561/580-660 nm) channels with a xy resolution of 0.13 µm and the section thickness 517 of 1.2 µm. Fluorescence images were filtered with a median filter (kernel size: 0.25 × 518 0.25 µm) for presentation purposes. 519 520
Automated microscopy and analysis 521
For continuous live-cell imaging of HeLa Kyoto Mad2L1-EGFP cells stably expressing 522
LAMAs, cells were seeded in 96-well plates (Eppendorf), in the presence of TMP (50 523 µM). After cells were adherent, cells were labeled with BG-SiR (100 nM) overnight. 524
The cells were then labeled with Hoechst 33342 (1 µg/ mL) in complete medium 525 without phenol red in the presence or absence of TMP (50 µM) for 15 min, and washed 526 3 times with complete medium without phenol red in the presence or absence of TMP 527 (50 µM). Cells were imaged in the presence of BG-SiR (100 nM), in the presence or 528 absence of TMP (50 µM), and in the presence of additional mitotic drugs as indicated, 529 nocodazole (330 nM) or reversine (5 µM). Automatic microscopy was performed with 530
Leica HCS A Matrix Screener software on a Leica DMi8 microscope (Leica 531 Microsystems, Germany) equipped with a Leica TCS SP8 X scanhead; a SuperK white 532
